What Happened?
Charlottesville, AB-based ZielBio Appointed Kimberly Kelly as Founder
About the Company
ZielBio is an early-stage biotechnology company that identifies novel high value disease targets and develops therapeutic interventions to improve patient outcomes. Our proprietary drug discovery platform Zielfind™ combines the power of functional, high throughput screening with large content data analytics to identify high value targets. We have a promising pipeline of therapies and targets, including lead compound ZB131, a proprietary humanized monoclonal antibody against cell surface plectin (CSP) a cancer target identified through Zielfind™.
About the Person
Kimberly Kelly is Founder at ZielBio. Previously, Kimberly held various senior HR leadership roles in the industry.
Info Source
News
Short Profile